Scoop: Clinigen acquiring SSI Strategy for high-teens multiple

Triton-backed Clinigen is paying a high-teens EBITDA multiple for biotech consultancy SSI Strategy, two sources familiar with the situation say.

Why it matters: PE-backed pharma services businesses continue to command rich valuations.